<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:voc="urn:hl7-org:v3/voc" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f729e800-0b53-25a7-f7dc-bee3bdf29882"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BROMFENAC OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for BROMFENAC OPHTHALMIC SOLUTION.<br/>BROMFENAC ophthalmic solution, 0.07%, for topical ophthalmic use<br/>
      <br/>Initial U.S. Approval: 1997</title>
   <effectiveTime value="20250320"/>
   <setId root="4246c669-3c2a-2a2b-3b1c-696deb4ab519"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="845263701" root="1.3.6.1.4.1.519.1"/>
            <name>Apotex Corp.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="209429182" root="1.3.6.1.4.1.519.1"/>
                  <name>Apotex Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="255092496" root="1.3.6.1.4.1.519.1"/>
                        <name>Apotex Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-1006" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-1006" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="7542e5ce-1785-9e3b-8fa9-ebb417e1748b"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250320"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-1006" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Bromfenac Ophthalmic Solution, 0.07%</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Bromfenac Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="0.7"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8ECV571Y37" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BROMFENAC SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="864P0921DW" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BROMFENAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.05"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91MBZ8H3QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BORATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VTK01UQK3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM SULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Y27PUL9H56" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TYLOXAPOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1.6"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-1006-1"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240711"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="3"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-1006-2"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240711"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA207334" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240711"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <section>
                     <id root="37522458-c0dd-1e2a-52e0-16e5d1c6b210"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <effectiveTime value="20140523"/>
                     <component>
                        <observationMedia ID="MM609678731787">
                           <text>Bottle</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="Bottle.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_de595b1a-5cc0-49a7-8dd2-23decaddc00f">
               <id root="f6fe9816-9769-085d-f355-a3505393d4b7"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.</paragraph>
               </text>
               <effectiveTime value="20170301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Bromfenac Ophthalmic Solution, 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. (<linkHtml href="#i4i_indications_id_de595b1a-5cc0-49a7-8dd2-23decaddc00f">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_5eb48697-4ef6-4d98-80c2-f2b631479ae6">
               <id root="90a4ca94-eb4c-f708-4af7-185e3ddfac36"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20130319"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days post-surgery. (<linkHtml href="#i4i_dosage_admin_duplicate_id_6013d032-ced5-4ffa-b925-62119c327b90">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_dosage_admin_duplicate_id_6013d032-ced5-4ffa-b925-62119c327b90">
                     <id root="0d816254-9533-789e-f2bd-cfaa36309889"/>
                     <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>Apply one drop to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_dosage_admin_duplicate_id_826ae0f8-206b-4993-ad92-06675c5d07b4">
                     <id root="890e79ea-6052-9c91-5481-d8660daea708"/>
                     <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2 Use with Other Topical Ophthalmic Medications</title>
                     <text>
                        <paragraph>Bromfenac ophthalmic solution, 0.07% may be administered in conjunction with other topical ophthalmic medications such as alpha agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_form_strength_id_7fe169aa-0959-4652-8be5-6ec1b5bfc63d">
               <id root="52680337-f965-60cc-847d-b5d0ef925e21"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Ophthalmic solution: bromfenac 0.07%</paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution: bromfenac 0.07% (<linkHtml href="#i4i_dosage_form_strength_id_7fe169aa-0959-4652-8be5-6ec1b5bfc63d">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_0b0c2372-bf11-4435-afb9-ac3b8abcbda1">
               <id root="8ce48af1-8191-4012-7258-21915f2e1d67"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#i4i_contraindications_id_0b0c2372-bf11-4435-afb9-ac3b8abcbda1">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_precautions_id_a157657e-50d4-4676-89d6-14e254d1c8eb">
               <id root="ec291b81-7bcf-4bc2-fe8e-d8e2b4c0ad72"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20130319"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• Sulfite Allergic Reactions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_454c8dc4-b58e-4c24-b7b1-0d739af3a261">5.1</linkHtml>)</paragraph>
                        <paragraph>• Slow or Delayed Healing (<linkHtml href="#i4i_warnings_precautions_duplicate_id_8e5200ab-8662-4ce5-bc3c-c1c11da63a3f">5.2</linkHtml>)</paragraph>
                        <paragraph>• Potential for Cross-Sensitivity (<linkHtml href="#i4i_warnings_precautions_duplicate_id_89acaac2-0567-4f21-a236-060040689e63">5.3</linkHtml>)</paragraph>
                        <paragraph>• Increased Bleeding Time (<linkHtml href="#i4i_warnings_precautions_duplicate_id_21574b27-1905-4b3e-a937-b0f7edcdfba3">5.4</linkHtml>)</paragraph>
                        <paragraph>• Keratitis and Corneal Reactions (<linkHtml href="#i4i_warnings_precautions_duplicate_id_39e917e3-55f9-4771-b65c-d62e06600480">5.5</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_454c8dc4-b58e-4c24-b7b1-0d739af3a261">
                     <id root="bdfc6b16-4f7a-ef2f-8e7b-2f617cc2b751"/>
                     <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.1 Sulfite Allergic Reactions</title>
                     <text>
                        <paragraph>Bromfenac ophthalmic solution, 0.07% contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_8e5200ab-8662-4ce5-bc3c-c1c11da63a3f">
                     <id root="d57bee14-0fef-f8ce-a978-ae1b7123fc60"/>
                     <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.2 Slow or Delayed Healing</title>
                     <text>
                        <paragraph>All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</paragraph>
                     </text>
                     <effectiveTime value="20130319"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_89acaac2-0567-4f21-a236-060040689e63">
                     <id root="5b5a6819-502a-3e76-674a-1c6eaad00538"/>
                     <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3 Potential for Cross-Sensitivity</title>
                     <text>
                        <paragraph>There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.</paragraph>
                     </text>
                     <effectiveTime value="20130319"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_21574b27-1905-4b3e-a937-b0f7edcdfba3">
                     <id root="9229873f-5dde-a8a7-6059-8292aa8e8095"/>
                     <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.4 Increased Bleeding Time</title>
                     <text>
                        <paragraph>With some NSAIDs, including bromfenac, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.</paragraph>
                        <paragraph>It is recommended that bromfenac ophthalmic solution, 0.07% be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.</paragraph>
                     </text>
                     <effectiveTime value="20130319"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_39e917e3-55f9-4771-b65c-d62e06600480">
                     <id root="a4985fd3-7619-7510-717c-316e105bd507"/>
                     <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.5 Keratitis and Corneal Reactions</title>
                     <text>
                        <paragraph>Use of topical NSAIDs, including bromfenac, may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health.</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days postsurgery may increase patient risk for the occurrence and severity of corneal adverse events.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="_a2625d46-57f6-f5b5-cdeb-a64251feac13">
                     <id root="686d8260-772d-f3f5-900d-4c5d94e0822d"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.6 Risk of Contamination</title>
                     <text>
                        <paragraph>Do not touch dropper tip to the eye, eyelids, or to any surface, as this may contaminate the contents. Replace the bottle cap after using.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_warnings_precautions_duplicate_id_1ddee7be-adb6-434f-a353-8a87c989e1cf">
                     <id root="a8d9b76e-c6c2-f2fa-8db7-230f8a50c22b"/>
                     <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.7 Contact Lens Wear</title>
                     <text>
                        <paragraph>Bromfenac ophthalmic solution, 0.07% should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of bromfenac ophthalmic solution, 0.07%. The preservative in bromfenac ophthalmic solution, 0.07%, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution, 0.07%.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_db59bf32-cf56-4aa6-a77a-b03479725664">
               <id root="e4d356ef-bcaa-c887-4a47-bccc07e800a9"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20240531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision (<linkHtml href="#i4i_adverse_effects_duplicate_id_f8f4952f-d803-45de-b71b-cb90bcd66db3">6.1</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact <content styleCode="bold"> Apotex Corp. at 1-800-706-5575,</content> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch"> www.fda.gov/medwatch</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_adverse_effects_duplicate_id_f8f4952f-d803-45de-b71b-cb90bcd66db3">
                     <id root="0cb45724-1e65-98c8-0cf7-1552992d8a60"/>
                     <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The most commonly reported adverse reactions following use of bromfenac ophthalmic solution, 0.07% following cataract surgery include: anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. These reactions were reported in 3% to 8% of patients.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_specific_populations_id_542f6143-aef0-47b9-b653-8385576f503a">
               <id root="b3dec51c-7592-ab3f-60be-815d54783978"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20130319"/>
               <component>
                  <section ID="i4i_pregnancy_id_4f2e2c5d-36fe-4350-81ce-7acfc5fb3e4d">
                     <id root="75b2a642-1859-789a-a9b3-15207a3928b7"/>
                     <code code="42228-7" displayName="PREGNANCY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on bromfenac ophthalmic solution, 0.07% use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. </paragraph>
                        <paragraph>  The systemic exposure to bromfenac following topical ocular administration is low <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_39556017-1a11-4961-9085-e412ea3c9a74">12.3</linkHtml>)].</content> Consequently, the systemic exposure of a pregnant woman to bromfenac is expected to be minimal following topical ocular administration. </paragraph>
                        <paragraph> However, because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution, 0.07% during late pregnancy should be avoided.</paragraph>
                        <paragraph> The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Premature closure of the ductus arteriosus in the fetus has occurred with third trimester use of oral and injectable NSAIDs. Measurable maternal and fetal plasma drug levels are available with oral and injectable routes of NSAID administration. The maternal plasma level of bromfenac ophthalmic solution, 0.07% following ocular administration is unknown <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#i4i_pharmacokinetics_id_39556017-1a11-4961-9085-e412ea3c9a74">12.3</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Embryo-fetal lethality and maternal toxicity were produced in rats and rabbits treated with bromfenac during the period of organogenesis at oral doses up to 0.9 mg/kg/day and 7.5 mg/kg/day, respectively. These doses corresponded to a C<sub>max</sub> 90- and 150- times that predicted C<sub>max</sub> at the recommended human ophthalmic dose (RHOD), respectively. In rats, bromfenac treatment caused delayed parturition at 0.3 mg/kg/day (30 times the predicted human C<sub>max</sub> at the RHOD), and caused dystocia, increased neonatal mortality, and reduced postnatal growth at 0.9 mg/kg/day (90 times the predicted human C<sub>max</sub> at the RHOD).</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="_0597c8a6-6829-867d-138c-10fb66892d36">
                     <id root="8789f678-676d-bded-de5c-7c0958b84b29"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>There are no data on the presence of bromfenac in human milk, the effects on the breastfed infant, or the effects on milk production. </paragraph>
                        <paragraph> The systemic exposure of a breastfeeding woman to bromfenac is expected to be minimal following topical ocular administration, however, the possibility of harm to the breastfed infant cannot be ruled out. </paragraph>
                        <paragraph> The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for bromfenac ophthalmic solution, 0.07%, and any potential adverse effects on the breastfed infant from bromfenac ophthalmic solution, 0.07% or from the underlying maternal conditions.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_81c7a033-0a61-4a21-bd33-55bda627e7df">
                     <id root="503ac968-55d6-95d4-edb8-3613824c00f0"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of bromfenac ophthalmic solution, 0.07% have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_1cb2dfd2-67d5-4ccc-ae45-06bfec56eff6">
                     <id root="d1baf825-6e4c-a3bc-268f-08fb800a0ce7"/>
                     <code code="34082-8" displayName="GERIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness of bromfenac ophthalmic solution, 0.07% have been observed between patients 70 years of age and older and younger adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_f0dff46b-4883-4864-941d-2a09b191a880">
               <id root="beea51da-53b2-42fb-706a-0b691d793a9a"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Bromfenac Ophthalmic Solution, 0.07% is a sterile, nonsteroidal anti-inflammatory drug (NSAID) for topical ophthalmic use. Each mL of Bromfenac Ophthalmic Solution, 0.07% contains 0.805 mg bromfenac sodium sesquihydrate (equivalent to 0.7 mg bromfenac free acid). The USAN name for bromfenac sodium sesquihydrate is bromfenac sodium. Bromfenac sodium is designated chemically as sodium [2-amino-3-(4-bromobenzoyl) phenyl] acetate sesquihydrate, with an empirical formula of C<sub>15</sub>H<sub>11</sub>BrNNaO<sub>3</sub>• 1½ H<sub>2</sub>O. The chemical structure for bromfenac sodium sesquihydrate is:</paragraph>
                  <renderMultiMedia referencedObject="id_a6e02c75-cab7-48a4-806a-f38f98233557"/>
                  <paragraph>Bromfenac sodium is a yellow to orange crystalline powder. The molecular weight of bromfenac sodium is 383.17. Bromfenac Ophthalmic Solution, 0.07% is supplied as a sterile aqueous 0.07% solution, with a pH of 7.8. The osmolality of Bromfenac Ophthalmic Solution, 0.07% is approximately 300 mOsmol/kg.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Each mL of Bromfenac Ophthalmic Solution, 0.07% contains:</content>
                  </paragraph>
                  <paragraph> <content styleCode="bold">Active</content>: Each mL contains bromfenac sodium sesquihydrate 0.0805%, which is equivalent to bromfenac free acid 0.07%.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative</content>: benzalkonium chloride 0.005%</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactives</content>: boric acid, edetate disodium dihydrate, povidone, sodium borate, sodium sulfite, tyloxapol, sodium hydroxide to adjust pH and water for injection.</paragraph>
               </text>
               <effectiveTime value="20250320"/>
               <component>
                  <observationMedia ID="id_a6e02c75-cab7-48a4-806a-f38f98233557">
                     <text>Chemical-Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_6f00264b-e16e-4881-baf9-94b45e075051">
               <id root="23694c59-c6fb-4d40-0a75-cb46acc44bad"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20130319"/>
               <component>
                  <section ID="i4i_mechanism_action_id_7fb5b0ae-0c4d-4e50-8f8e-af8ec105dd28">
                     <id root="2fbfa3c3-f452-b1cb-4bfa-9eebe5f6b083"/>
                     <code code="43679-0" displayName="MECHANISM OF ACTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.</paragraph>
                     </text>
                     <effectiveTime value="20130319"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pharmacokinetics_id_39556017-1a11-4961-9085-e412ea3c9a74">
                     <id root="19d95f66-102b-113e-12f6-51d7de743f80"/>
                     <code code="43682-4" displayName="PHARMACOKINETICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The plasma concentration of bromfenac following ocular administration of 0.07% bromfenac ophthalmic solution in humans is unknown. Based on the maximum proposed dose of one drop to each eye (0.035 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.</paragraph>
                     </text>
                     <effectiveTime value="20130319"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_nonclinical_toxicology_id_6f1353c6-0f6c-4055-9a26-1402a37ea250">
               <id root="bc2812f9-80a5-5eb8-56a8-adeb2adfa99f"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20130319"/>
               <component>
                  <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_de1baaa9-ae11-4693-8d94-43f2fdc4c5fc">
                     <id root="e9078215-286d-5dce-4c77-c417dad41c65"/>
                     <code code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (systemic exposure 30 times the systemic exposure predicted from RHOD assuming the human systemic concentration is at the limit of quantification) and 5 mg/kg/day (340 times the predicted human systemic exposure), respectively, revealed no significant increases in tumor incidence.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (systemic exposure 90 and 30 times the predicted human exposure, respectively).</paragraph>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_studies_id_c9e22549-a81d-410c-b70b-9ae0a114f1c0">
               <id root="e551175c-bd84-814e-265e-ccb621c82bef"/>
               <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20130319"/>
               <component>
                  <section ID="i4i_clinical_studies_duplicate_id_a034b30b-a445-4fb0-96ff-8c0b143475ac">
                     <id root="99d66359-759a-b15e-85a7-c565aadf7c87"/>
                     <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.1 Ocular Inflammation and Pain</title>
                     <text>
                        <paragraph>Bromfenac 0.07% QD for the treatment of postoperative inflammation and reduction of ocular pain was evaluated in two multi-center, randomized, double-masked, parallel-group, and placebo (vehicle)-controlled studies. Patients undergoing cataract surgery self-administered bromfenac 0.07% or vehicle once daily, beginning 1 day prior to surgery, continuing on the morning of surgery and for 14 days after surgery.  Complete clearance of ocular inflammation (0 cell and no flare) was assessed on Days 1, 3, 8, and 15 postsurgery using slit lamp biomicroscopy. The pain score was self-reported. The primary efficacy endpoint was the proportion of subjects who had complete clearance of ocular inflammation by Day 15. In the intent-to-treat analyses from both assessments, complete clearance at Day 8 and Day 15, bromfenac 0.07% was superior to vehicle as shown in the following table.</paragraph>
                        <table ID="id_991061aa-4d90-462e-8aae-73455614991f" border="single" width="443">
                           <col width="13.6%"/>
                           <col width="20.5%"/>
                           <col width="23.2%"/>
                           <col width="19.1%"/>
                           <col width="23.5%"/>
                           <tbody>
                              <tr ID="id_493f2fb7-2c0a-4fd9-a788-67b0e8e9c21d">
                                 <td align="left" colspan="5" styleCode="Lrule Botrule Rrule" valign="top">Proportion of Subjects with Cleared Ocular Inflammation (0 cell and no flare)</td>
                              </tr>
                              <tr ID="id_89c72cf3-c742-4d8b-926f-0a39efbdb151">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">Study</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Visit</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Bromfenac 0.07%</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Vehicle</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Difference (%)</paragraph>
                                    <paragraph/>(Asymptotic 95% CI)</td>
                              </tr>
                              <tr ID="id_cc7e6391-334a-45c4-a673-ec8fe8f90f82">
                                 <td align="left" rowspan="2" styleCode="Lrule Botrule Rrule" valign="top">Study 1</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">At Day 8</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">27/112<paragraph/> (24.1%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">7/108 <paragraph/>(6.5%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">17.6 <paragraph/>(8.4, 26.8)</td>
                              </tr>
                              <tr ID="id_100d40b1-9131-4d00-99aa-043ff6e1250c">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">At Day 15</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">51/112<paragraph/> (45.5%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">14/108 <paragraph/>(13.0%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">32.5<paragraph/> (21.4, 43.8)</td>
                              </tr>
                              <tr ID="id_5d3edfa4-51c3-47a0-8b61-78821792dd1d">
                                 <td align="left" rowspan="2" styleCode="Lrule Botrule Rrule" valign="top">Study 2</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">At Day 8</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">33/110<paragraph/> (30.0%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">14/110 <paragraph/>(12.7%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">17.3<paragraph/> (6.7, 27.9)</td>
                              </tr>
                              <tr ID="id_c1774ca1-001f-41b6-b1d0-78b60d98c3ca">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">At Day 15</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">50/110 <paragraph/>(45.5%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">30/110 <paragraph/>(27.3%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">18.2<paragraph/> (5.7, 30.7)</td>
                              </tr>
                              <tr ID="id_c9a810c9-fed4-49b0-ad09-c6fc7066c0b2">
                                 <td align="left" colspan="5" styleCode="Lrule Botrule Rrule" valign="top">Proportion of Subjects Who Were Pain Free</td>
                              </tr>
                              <tr ID="id_e1dcd1b7-0d0a-44b3-8fd3-da53c5c56b97">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">Study</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Visit</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Bromfenac 0.07%</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">Vehicle</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">
                                    <paragraph>Difference (%)</paragraph>
                                    <paragraph/>(Asymptotic 95% CI)</td>
                              </tr>
                              <tr ID="id_906ecc2e-4324-451c-8655-0df7a5da3f1c">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">Study 1</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">At Day 1</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">91/112<paragraph/> (81.3%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">47/108 <paragraph/>(43.5%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">37.7<paragraph/> (25.9, 49.6)</td>
                              </tr>
                              <tr ID="id_ae66aaf2-9955-49ea-8280-3c82a8178561">
                                 <td align="left" styleCode="Lrule Botrule Rrule" valign="top">Study 2</td>
                                 <td align="left" styleCode="Rrule" valign="top">At Day 1</td>
                                 <td align="left" styleCode="Rrule" valign="top">84/110<paragraph/> (76.4%)</td>
                                 <td align="left" styleCode="Rrule" valign="top">61/110 <paragraph/>(55.5%)</td>
                                 <td align="left" styleCode="Botrule Rrule" valign="top">20.9<paragraph/> (8.7, 33.1)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_b83e9b37-0c27-4bb7-99a9-464069bf1f5f">
               <id root="aabdaa4d-c350-6d14-a663-17102be9e7f8"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Bromfenac Ophthalmic Solution, 0.07% is supplied in a white opaque LDPE plastic bottle with a white translucent LDPE dropper and gray opaque HDPE plastic cap as follows:</paragraph>
                  <paragraph>• 1.6 mL in a 5 mL container (NDC 60505-1006-1)</paragraph>
                  <paragraph>• 3 mL in a 5 mL container (NDC 60505-1006-2)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content> Store at 20ºC to 25ºC (68ºF to 77ºF) [See USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20250320"/>
            </section>
         </component>
         <component>
            <section ID="i4i_info_patients_id_610059a7-8310-4b0d-8128-5ddf40670744">
               <id root="d3212c34-3706-9a52-c20a-a5b73e3d91e7"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Slow or Delayed Healing</content>
                  </paragraph>
                  <paragraph> Advise patients of the possibility that slow or delayed healing may occur while using NSAIDs. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Risk of Contamination </content>
                  </paragraph>
                  <paragraph>Advise patients to not touch dropper tip to the eye, eyelids, or to any surface, as this may contaminate the contents. Advise patients to replace bottle cap after using. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Contact Lens Wear</content>
                  </paragraph>
                  <paragraph> Advise patients to remove contact lenses prior to instillation of bromfenac ophthalmic solution, 0.07%. The preservative in bromfenac ophthalmic solution, 0.07%, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution, 0.07%. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Use with Other Topical Ophthalmic Medications</content>
                  </paragraph>
                  <paragraph> Advise patients that if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.</paragraph>
                  <table>
                     <tbody>
                        <tr>
                           <td>Manufactured by:</td>
                           <td>Manufactured for:</td>
                        </tr>
                        <tr>
                           <td>Apotex Inc.</td>
                           <td>Apotex Corp.</td>
                        </tr>
                        <tr>
                           <td>Toronto, Ontatio</td>
                           <td>Weston, FL</td>
                        </tr>
                        <tr>
                           <td>Canada M9L 1T9</td>
                           <td>33326</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>March 2025</paragraph>
               </text>
               <effectiveTime value="20250320"/>
            </section>
         </component>
         <component>
            <section ID="_64d6a312-79c1-551f-80cd-fa4f7d7b2467">
               <id root="af27c623-159b-967e-7cac-a9c9bc712018"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION</title>
               <text>
                  <paragraph>NDC 60505-1006-2</paragraph>
                  <paragraph>Bromfenac Ophthalmic Solution, 0.07% </paragraph>
                  <paragraph>Sterile</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>3 mL</paragraph>
                  <paragraph>Once Daily</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM609678731787"/>
                  </paragraph>
               </text>
               <effectiveTime value="20140523"/>
            </section>
         </component>
         <component>
            <section ID="i4i_Principal_display_panel_id_a2c0b7a7-2b85-4e65-ab18-0975f16d3419">
               <id root="58866f6b-a827-d714-e14f-5c8205f0f9f1"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia referencedObject="id_d64682f5-9a39-40f9-80bb-6ecb6dbe17c6"/>
                  <paragraph>NDC 60505-1006-2</paragraph>
                  <paragraph>Bromfenac Ophthalmic Solution, 0.07% </paragraph>
                  <paragraph>Sterile</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>3 mL</paragraph>
                  <paragraph>Once Daily</paragraph>
               </text>
               <effectiveTime value="20130319"/>
               <component>
                  <observationMedia ID="id_d64682f5-9a39-40f9-80bb-6ecb6dbe17c6">
                     <text>Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>